Patents by Inventor Kathrin STIRNEMANN

Kathrin STIRNEMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATION OF NKT CELL ACTIVITY WITH ANTIGEN-LOADED CD1d MOLECULES
    Publication number: 20170312356
    Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a ?2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
    Type: Application
    Filed: February 8, 2017
    Publication date: November 2, 2017
    Applicant: VACCINEX, INC.
    Inventors: Alena DONDA, Jean-Pierre MACH, Kathrin STIRNEMANN, Maurice Zauderer
  • Modulation of NKT cell activity with antigen-loaded CD1d molecules
    Patent number: 9603922
    Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a ?2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: March 28, 2017
    Assignee: VACCINEX, INC.
    Inventors: Alena Donda, Jean-Pierre Mach, Kathrin Stirnemann
  • Modulation of NKT Cell Activity with Antigen-Loaded CD1d Molecules
    Publication number: 20080254045
    Abstract: The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a ?2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.
    Type: Application
    Filed: February 21, 2008
    Publication date: October 16, 2008
    Inventors: Alena DONDA, Jean-Pierre MACH, Kathrin STIRNEMANN, Maurice ZAUDERER